Pfizer reaches deals to delay generic heart drug rivals until 2031
Pfizer settled patent disputes with three generic drugmakers over its heart medication. These deals delay cheaper competition for the drug until 2031.
Xurve View
Insights:
Xurve View
PFIZER INC reached settlement agreements with three generic drugmakers to delay cheaper heart drug versions until 2031. The deal extends patent protection for the United States pharmaceutical company by five years. Investors gain revenue certainty as Pfizer protects a key franchise from immediate low-cost competition.
